Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6 months in primary ciliary dyskinesia

BMC Pulmonary Medicine

Volumn 16, Issue 1, 2016, Pages

  Kobbernagel, Helene E ^a   Buchvald, Frederik F ^a   Haarman, Eric G ^b   Casaulta, Carmen ^c   Collins, Samuel A ^d   Hogg, Claire ^e   Kuehni, Claudia E ^c   Lucas, Jane S ^d   Omran, Heymut ^f   Quittner, Alexandra L ^g   Werner, Claudius ^f   Nielsen, Kim G ^a  

^a International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g University of Miami   (United States)

Author keywords

Azithromycin; Exacerbation; Health related quality of life; Lung clearance index; Multiple breath washout; Primary ciliary dyskinesia; QOL PCD

Indexed keywords

ALANINE AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; C REACTIVE PROTEIN; CLARITHROMYCIN; COLISTIN; CREATININE; HEMOGLOBIN; PENICILLIN DERIVATIVE; PLACEBO; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ACHROMOBACTER XYLOSOXIDANS; ACHROMOBACTER XYLOSOXIDANS INFECTION; ADOLESCENT; ADULT; AGE DISTRIBUTION; AIRWAY; AIRWAY RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; BODY WEIGHT; BURKHOLDERIA INFECTION; CHILD; CILIARY DYSKINESIA; CLINICAL PROTOCOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EAR DISEASE; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GRAM NEGATIVE BACTERIUM; HEARING IMPAIRMENT; HUMAN; LEUKOCYTE COUNT; LEUKOCYTE DIFFERENTIAL COUNT; LUNG FUNCTION; LUNG INFECTION; LUNG VOLUME; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; MYCOBACTERIUM TUBERCULOSIS; PHYSICAL EXAMINATION; PLETHYSMOGRAPHY; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RESPIRATORY SINUS; RESPIRATORY TRACT DISEASE; RESPIROMETRY; SCHOOL CHILD; SIDE EFFECT; SINUS CONGESTION; SPUTUM; THROMBOCYTE; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT REFUSAL; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; EUROPE; FEMALE; KARTAGENER SYNDROME; MALE; METHODOLOGY; MIDDLE AGED; REGRESSION ANALYSIS; RESPIRATORY TRACT INFECTIONS; SPIROMETRY; TREATMENT OUTCOME; VITAL CAPACITY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; KARTAGENER SYNDROME; MALE; MIDDLE AGED; QUALITY OF LIFE; REGRESSION ANALYSIS; RESEARCH DESIGN; RESPIRATORY TRACT INFECTIONS; SPIROMETRY; TREATMENT OUTCOME; VITAL CAPACITY; YOUNG ADULT;

EID: 84979084506     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-016-0261-x     Document Type: Article

References (45)

1. Barbato A, Frischer T, Kuehni CE, Snijders D, Azevedo I, Baktai G, Bartoloni L, Eber E, Escribano A, Haarman E, et al. Primary ciliary dyskinesia: a consensus statement on diagnostic and treatment approaches in children. Eur Respir J. 2009;34:1264-76.
2. Knowles MR, Daniels LA, Davis SD, Zariwala MA, Leigh MW. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med. 2013;188:913-22.
3. Stillwell PC, Wartchow EP, Sagel SD. Primary ciliary dyskinesia in children: a review for pediatricians, allergists, and pediatric pulmonologists. Pediatr Allergy Immunol Pulmonol. 2011;24:191-6.
4. Rogers GB, Carroll MP, Zain NM, Bruce KD, Lock K, Walker W, Jones G, Daniels TW, Lucas JS. Complexity, temporal stability, and clinical correlates of airway bacterial community composition in primary ciliary dyskinesia. J Clin Microbiol. 2013;51:4029-35.
5. Alanin MC, Nielsen KG, von Buchwald C, Skov M, Aanaes K, Hoiby N, Johansen HK. A longitudinal study of lung bacterial pathogens in patients with primary ciliary dyskinesia. Clin Microbiol Infect. 2015;21:1093-7.
6. Bush A, Chodhari R, Collins N, Copeland F, Hall P, Harcourt J, Hariri M, Hogg C, Lucas J, Mitchison HM, et al. Primary ciliary dyskinesia: current state of the art. Arch Dis Child. 2007;92:1136-40.
7. Lucas JS, Burgess A, Mitchison HM, Moya E, Williamson M, Hogg C. Diagnosis and management of primary ciliary dyskinesia. Arch Dis Child. 2014;99:850-6.
8. Kuehni CE, Frischer T, Strippoli MP, Maurer E, Bush A, Nielsen KG, Escribano A, Lucas JS, Yiallouros P, Omran H, et al. Factors influencing age at diagnosis of primary ciliary dyskinesia in European children. Eur Respir J. 2010;36:1248-58.
9. Cohen-Cymberknoh M, Simanovsky N, Hiller N, Gileles HA, Shoseyov D, Kerem E. Differences in disease expression between primary ciliary dyskinesia and cystic fibrosis with and without pancreatic insufficiency. Chest. 2014;145:738-44.
10. Shapiro AJ, Zariwala MA, Ferkol T, Davis SD, Sagel SD, Dell SD, Rosenfeld M, Olivier KN, Milla C, Daniel SJ, et al. Diagnosis, monitoring, and treatment of primary ciliary dyskinesia: PCD foundation consensus recommendations based on state of the art review. Pediatr Pulmonol. 2016;51:115-32.
11. Werner C, Onnebrink JG, Omran H. Diagnosis and management of primary ciliary dyskinesia. Cilia. 2015;4:2.
12. Strippoli MP, Frischer T, Barbato A, Snijders D, Maurer E, Lucas JS, Eber E, Karadag B, Pohunek P, Zivkovic Z, et al. Management of primary ciliary dyskinesia in European children: recommendations and clinical practice. Eur Respir J. 2012;39:1482-91.
13. Spagnolo P, Fabbri LM, Bush A. Long-term macrolide treatment for chronic respiratory disease. Eur Respir J. 2013;42:239-51.
14. Wilms EB, Touw DJ, Heijerman HG, van der Ent CK. Azithromycin maintenance therapy in patients with cystic fibrosis: a dose advice based on a review of pharmacokinetics, efficacy, and side effects. Pediatr Pulmonol. 2012;47:658-65.
15. Haworth CS, Bilton D, Elborn JS. Long-term macrolide maintenance therapy in non-CF bronchiectasis: evidence and questions. Respir Med. 2014;108:1397-408.
16. Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2012;11:CD002203.
17. Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2010;303:1707-15.
18. Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380:660-7.
19. Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA. 2013;309:1251-9.
20. Valery PC, Morris PS, Byrnes CA, Grimwood K, Torzillo PJ, Bauert PA, Masters IB, Diaz A, McCallum GB, Mobberley C, et al. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial. Lancet Respir Med. 2013;1:610-20.
21. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper Jr JA, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689-98.
22. Yousef AA, Jaffe A. The role of azithromycin in patients with cystic fibrosis. Paediatr Respir Rev. 2010;11:108-14.
23. Lucas JS, Behan L, Dunn GA, Alpern A, Morris AM, Carroll MP, Knowles MR, Leigh MW, Quittner AL. A quality-of-life measure for adults with primary ciliary dyskinesia: QOL-PCD. Eur Respir J. 2015;46:375-83.
24. Leigh MW, Hazucha MJ, Chawla KK, Baker BR, Shapiro AJ, Brown DE, Lavange LM, Horton BJ, Qaqish B, Carson JL, et al. Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia. Ann Am Thorac Soc. 2013;10:574-81.
25. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-38.
26. Stanojevic S, Wade A, Stocks J, Hankinson J, Coates AL, Pan H, Rosenthal M, Corey M, Lebecque P, Cole TJ. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med. 2008;177:253-60.
27. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26:511-22.
28. Robinson PD, Latzin P, Verbanck S, Hall GL, Horsley A, Gappa M, Thamrin C, Arets HG, Aurora P, Fuchs SI, et al. Consensus statement for inert gas washout measurement using multiple- and single- breath tests. Eur Respir J. 2013;41:507-22.
29. Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, Grimsey NJ, Cusens D, Coulter S, Cooper J, et al. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest. 2011;121:3554-63.
30. Elborn JS, Tunney MM. Macrolides and bronchiectasis: clinical benefit with a resistance price. JAMA. 2013;309:1295-6.
31. Pifferi M, Bush A, Pioggia G, Caramella D, Tartarisco G, Di CM, Zangani M, Chinellato I, Maggi F, Tezza G, et al. Evaluation of pulmonary disease using static lung volumes in primary ciliary dyskinesia. Thorax. 2012;67:993-9.
32. Green K, Buchvald FF, Marthin JK, Hanel B, Gustafsson PM, Nielsen KG. Ventilation inhomogeneity in children with primary ciliary dyskinesia. Thorax. 2012;67:49-53.
33. Madsen A, Green K, Buchvald F, Hanel B, Nielsen KG. Aerobic fitness in children and young adults with primary ciliary dyskinesia. PLoS One. 2013;8:e71409.
34. Boon M, Vermeulen FL, Gysemans W, Proesmans M, Jorissen M, De BK. Lung structure-function correlation in patients with primary ciliary dyskinesia. Thorax. 2015;70:339-45.
35. Irving SJ, Ives A, Davies G, Donovan J, Edey AJ, Gill SS, Nair A, Saunders C, Wijesekera NT, Alton EW, et al. Lung clearance index and high-resolution computed tomography scores in primary ciliary dyskinesia. Am J Respir Crit Care Med. 2013;188:545-9.
36. Kent L, Reix P, Innes JA, Zielen S, Le BM, Braggion C, Lever S, Arets HG, Brownlee K, Bradley JM, et al. Lung clearance index: evidence for use in clinical trials in cystic fibrosis. J Cyst Fibros. 2014;13:123-38.
37. Davies J, Sheridan H, Bell N, Cunningham S, Davis SD, Elborn JS, Milla CE, Starner TD, Weiner DJ, Lee PS, et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. Lancet Respir Med. 2013;1:630-8.
38. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW, III. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290:1749-56.
39. Goss CH, Quittner AL. Patient-reported outcomes in cystic fibrosis. Proc Am Thorac Soc. 2007;4:378-86.
40. Quittner AL, O'Donnell AE, Salathe MA, Lewis SA, Li X, Montgomery AB, O'Riordan TG, Barker AF. Quality of life questionnaire-bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax. 2015;70:12-20.
41. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135:1223-32.
42. Summary of Product Characteristics: AZITROMYCINE CF 250 mg film-coated tablets, RVG 32493. Centrafarm B.V. Authorization: 06-04-2006; Revised 02-09-2013.
43. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official J Eur Communities L121, 34-44. 2001.
44. Clinical Trials Facilitation Groups. Guidance document for sponsors for a Voluntary Harmonisation Procedure (VHP) for the assessment of multinational Clinical Trial Applications, Version 3.1. CTFG//VHP/2013/Rev1. 2013.
45. BESTCILIA. www.bestcilia.eu. Accessed 25 Apr 2016.